巻号一覧
116 巻, 1 号
選択された号の論文の6件中1～6を表示しています
- |<
- <
- 1
- >
- >|
-
吉井 英一1996 年 116 巻 1 号 p. 1-20
発行日: 1996/01/25
公開日: 2008/05/30
ジャーナル フリーAchievements in the synthestic study on cardiotonic steroids, pyranonaphthoquinone antibiotics, and tetronic acid ionophore antibiotics from author's laboratory are reviewed.抄録全体を表示PDF形式でダウンロード (1286K) -
服部 成介, 馬場 広子1996 年 116 巻 1 号 p. 21-38
発行日: 1996/01/25
公開日: 2008/05/30
ジャーナル フリーThe proto-oncogene ras is an essential gene for the growth and the differentiation for various types of cells. Ras, ras gene product, is a GTP binding protein which controls the signal transduction by GTP hydrolysis. The ras gene is frequently activated by point mutations in various types of human cancers, which results in a decrease in the GTPase activity of its product. A GTPase-activating protein p120 (p120GAP) was identified as a factor which stimulates the GTPase of normal ras gene product p21 but not of the mutated. An NF1 gene was identified as a gene whose loss of function causes an onset of human disorder, neurofibromatosis type I. The NF1 gene encodes a protein which contains a region with a similarity to the catalytic domain of p120GAP. We recently purified a novel Ras GAP whose molecular weight and immunogenecity are different from those of p120GAP and NF1. We named the novel mammalian Ras GAP as Gap1m. Isolation and sequencing of Gap1m cDNA revealed that Gap1m is indeed a novel Ras GAP. We also succeeded in isolation of another novel Ras GAP gene, GapIII/Gap1IP4BP, which is closely related to Gap1m. Recently, it is shown that GapIII/Gap1IP4BP binds inositol-tetrakis phosphate compounds. The overview of these Ras GAP molecules is described.抄録全体を表示PDF形式でダウンロード (2345K) -
高橋 史郎, 高瀬 治登, 野村 泰治, 来間 和夫, 佐藤 尚志, 内田 清久1996 年 116 巻 1 号 p. 39-49
発行日: 1996/01/25
公開日: 2008/05/30
ジャーナル フリーTo quantify bile acids in biological samples, a solid phase extraction method was examined. This method is known as simpler procedures with less contamination compared with solvent extraction methods. Rat bile, feces and urine were used as biological samples. Since Bond Elut C18 and C8 were proved to be more suitable than the other phases (CH and SAX) so far examined using standard bile acids, Bond Elut C18 was used for biological samples. Quantification of biological sample was carried out by gas chromatography after the extracted sample was derivatized to methyl ester by treatment with trimethylsilyldiazomethane then to trifluoroacetyl ester by trifluoroacetic anhydride. On the gas chromatography, two columns (Rtx-50 and Rtx-200) were connected to the injector with Y-tube for elimination of interference. Except for a few bile acids, high recovery with less biological contamination was obtained by this solid phase extraction method.抄録全体を表示PDF形式でダウンロード (973K) -
味澤 幸義, 北澤 牧雄, 内田 雅彦, 小林 通洋1996 年 116 巻 1 号 p. 50-58
発行日: 1996/01/25
公開日: 2008/05/30
ジャーナル フリー2-Substituted malonamide derivatives were synthesized and tested for cholecystokinin A (CCK-A) receptor inhibitory activity. Significant CCK-A receptor inhibitory activities were found in only three compounds (4g-i) which have carboxyl group. In order to study structure-activity relationships, carboxyethyl group was selected for 2-substituent and a number of N-substituted malonamides were prepared. After these compounds were tested for CCK-A receptor inhibitory activity, 4-(3, 4-dichlorophenylcarbamoyl)-N, N-dipentylglutaramic acid (4h) was selected as the most preferred compound.抄録全体を表示PDF形式でダウンロード (696K) -
上田 條二, 門馬 則子, 山内 康彦, 吉江 文彦, 大澤 啓助1996 年 116 巻 1 号 p. 59-64
発行日: 1996/01/25
公開日: 2008/05/30
ジャーナル フリーA simple and precise method was established for the simultaneous determination of evodiamine and rutaecarpine in oriental pharmaceutical decoctions containing Evodia Fruit using high-performance liquid chromatography with sodium dodecyl sulfate (SDS) as an ion-pair reagent. Evodiamine and rutaecarpine were eluted within 60 min without interference from co-existing components using an ODS column and a mixture of water-methanol-acetonitrile-SDS-phosphoric acid (600 : 330 : 70 : 5 : 0.01, v/v/v/w/v, pH 5.0) as a mobile phase.抄録全体を表示PDF形式でダウンロード (592K) -
宮武 ノリヱ, 上原 真一, 西島 基弘1996 年 116 巻 1 号 p. 65-70
発行日: 1996/01/25
公開日: 2008/05/30
ジャーナル フリーThe stability and degradation pathways of phenyl salicylate (PS) in 50 v/v% aqueous ethanol were investigated over the pH range of 3.2-8.4. The experiments were performed at three different temperatures (5, 23 and 50°C) for four months by the use of high performance liquid chromatography. The degradation of PS was observed as a pseudo first-order kinetics not only in the alkaline region but in the acidic region and shown to proceed via transesterification (k1) and hydrolysis (k2) processes. The transesteified product, ethyl salicylate (ES), further underwent hydrolysis (k3)(k1>k2>k3). On the basis of kinetic studies, it was found that the degradation rate of PS decreased with decreasing pH and temperature. The half-lives of PS at pH 6.3 were 6.6d (50°C), 178d (23°C) and 2934d (5°C), respectively, and PS was stable at below ca. pH 4. On the other hand, PS in 100% ethanol also underwent the breakdown to ES by k1 process and its half-lives were 2.5d (50°C), 31.5d (23°C) and 257d (5°C), respectively. The present results is useful for the integrity of pharmaceutical formulations and delivery profiles.抄録全体を表示PDF形式でダウンロード (552K)
- |<
- <
- 1
- >
- >|